Mineralys Therapeutics (MLYS) Short-term Investments (2022 - 2026)

Mineralys Therapeutics has reported Short-term Investments for 5 years, with the latest figure at $533.3 million in Q1 2026.

• Quarterly Short-term Investments rose 199.61% year-over-year to $533.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $533.3 million (up 199.61% YoY) and the FY2025 annual result came in at $483.7 million, up 475.19% from the prior year.
• Short-term Investments advanced to $533.3 million in Q1 2026 per MLYS's latest filing, from $483.7 million in the prior quarter.
• Over five years, Short-term Investments peaked at $533.3 million in Q1 2026 and troughed at $22.4 million in Q4 2022.
• A 5-year average of $229.0 million and a median of $182.6 million in 2023 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments surged 735.66% in 2023, then sank 55.09% in 2024.
• Over 5 years, Short-term Investments stood at $22.4 million in 2022, then soared by 735.66% to $187.3 million in 2023, then tumbled by 55.09% to $84.1 million in 2024, then soared by 475.19% to $483.7 million in 2025, then rose by 10.25% to $533.3 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $533.3 million, $483.7 million, and $376.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.